Sino Medical Sciences Technology Inc. (SHA:688108)
China · Delayed Price · Currency is CNY 15.47
+0.15 (0.98%)
Sep 14, 2026, 11:29 AM CST
SHA:688108 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,403 | 8,005 | 4,035 | 5,146 | 2,341 | 3,366 | |
Market Cap Growth | -49.37% | 98.37% | -21.58% | 119.79% | -30.45% | -39.05% |
Enterprise Value | 6,199 | 7,926 | 4,078 | 5,109 | 2,260 | 3,101 |
Last Close Price | 15.32 | 19.24 | 9.76 | 12.55 | 5.71 | 8.21 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 74.78 | 169.28 | 2694.18 | - | - | - |
Forward PE | 85.11 | 178.98 | 81.33 | 70.82 | 70.82 | 64.39 |
PS Ratio | 10.86 | 15.24 | 8.80 | 14.99 | 12.14 | 17.32 |
PB Ratio | 5.97 | 8.34 | 4.49 | 5.97 | 2.64 | 3.56 |
P/TBV Ratio | 8.40 | 11.26 | 6.39 | 6.71 | 2.95 | 3.94 |
P/FCF Ratio | 37.72 | 68.96 | 65.91 | - | - | - |
P/OCF Ratio | 31.45 | 49.45 | 30.75 | 90.53 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 10.51 | 15.09 | 8.89 | 14.89 | 11.72 | 15.95 |
EV/EBITDA Ratio | 34.94 | 66.84 | 131.72 | - | - | - |
EV/EBIT Ratio | 56.02 | 143.76 | - | - | - | - |
EV/FCF Ratio | 36.52 | 68.29 | 66.61 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.14 | 0.22 | 0.25 | 0.23 | 0.07 | 0.05 |
Debt / EBITDA Ratio | 0.85 | 1.64 | 5.21 | - | - | - |
Debt / FCF Ratio | 0.89 | 1.82 | 3.68 | - | - | - |
Net Debt / Equity Ratio | -0.26 | -0.19 | -0.07 | 0.01 | -0.16 | -0.26 |
Net Debt / EBITDA Ratio | -1.62 | -1.56 | -2.15 | -0.45 | 0.84 | 2.14 |
Net Debt / FCF Ratio | -1.64 | -1.59 | -1.09 | -1.00 | 0.65 | 1.11 |
Asset Turnover | 0.44 | 0.40 | 0.37 | 0.31 | 0.18 | 0.17 |
Inventory Turnover | 2.07 | 2.03 | 1.86 | 1.35 | 0.94 | 0.81 |
Quick Ratio | 2.16 | 1.26 | 1.62 | 1.31 | 1.70 | 3.25 |
Current Ratio | 2.67 | 1.56 | 2.10 | 2.28 | 2.69 | 4.65 |
Return on Equity (ROE) | 9.00% | 5.11% | -0.44% | -4.96% | -18.91% | -12.98% |
Return on Assets (ROA) | 5.18% | 2.60% | -1.76% | -4.16% | -12.81% | -8.95% |
Return on Invested Capital (ROIC) | 10.89% | 4.76% | -4.11% | -9.29% | -30.81% | -26.91% |
Return on Capital Employed (ROCE) | 9.70% | 5.40% | -3.20% | -7.20% | -23.80% | -16.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.31% | 0.59% | 0.04% | -0.77% | -6.94% | -3.89% |
FCF Yield | 2.65% | 1.45% | 1.52% | -0.21% | -9.49% | -6.49% |
Payout Ratio | 4.28% | 8.87% | 274.39% | - | - | - |
Buyback Yield / Dilution | 5.05% | -14.80% | 5.51% | 2.38% | 0.66% | 0.33% |
Total Shareholder Return | 5.05% | -14.80% | 5.51% | 2.38% | 0.66% | 0.33% |